# Soleno Therapeutics (SLNO) Stock Analysis: An Eye on 116.89% Potential Upside

- Link: https://www.directorstalkinterviews.com/soleno-therapeutics-slno-stock-analysis-an-eye-on-116-89-potential-upside/4121217443
- Published: 2025-09-22T10:41:16+01:00
- Author: Madison Wilson

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is capturing investor attention with its
promising potential upside of 116.89%. As a clinical-stage biopharmaceutical company,
Soleno Therapeutics is at the forefront of developing innovative treatments for 
rare diseases, with its lead candidate aimed at tackling Prader-Willi Syndrome. 
Founded in 1999 and headquartered in Redwood City, California, the company is making
waves in the biotechnology sector.

Currently priced at $54.74, Soleno’s stock reflects a slight dip of 0.03%, yet remains
within a broad 52-week trading range of $42.54 to $88.49. This fluctuation, coupled
with a market capitalization of $2.91 billion, highlights investor interest and 
the inherent volatility often associated with biotech stocks, especially those in
the clinical trial phase.

Despite the absence of traditional valuation metrics such as P/E, PEG, and Price/
Sales ratios, Soleno’s stock is bolstered by strong analyst confidence. The company
boasts 11 buy ratings, with an average target price of $118.73, suggesting substantial
growth potential. The target price range between $106.00 and $145.00 further underscores
the bullish sentiment surrounding Soleno’s future prospects.

However, investors should be mindful of the company’s performance metrics. Soleno
reported a negative earnings per share (EPS) of -4.22 and a return on equity of -
69.53%, indicating a significant utilization of equity capital in pursuit of its
ambitious growth strategy. Additionally, the company’s free cash flow stands at -
$22.92 million, reflecting the financial strain typical for clinical-stage biopharmaceutical
firms.

From a technical standpoint, Soleno’s 50-day moving average is $74.17, while its
200-day moving average is $64.27. The current RSI (14) at 67.70 suggests the stock
is nearing overbought territory. Meanwhile, the MACD of -6.03 and a signal line 
of -5.34 may signal bearish momentum in the short term.

Despite these challenges, Soleno Therapeutics’ focus on Diazoxide Choline Extended-
Release tablets, now in Phase III clinical trials, represents a significant milestone.
This once-daily oral treatment for Prader-Willi Syndrome could be a game changer
in the rare disease market, potentially boosting the company’s financial and market
standing significantly.

For investors with a high-risk tolerance and an appetite for biotech innovation,
Soleno Therapeutics presents a compelling opportunity. As the company advances its
lead candidate through clinical trials, the potential for substantial returns remains
on the horizon. However, prospective investors should consider the inherent risks
associated with the biotech sector, including trial outcomes and regulatory approvals,
which could significantly impact Soleno’s stock performance.

Share on: